Novartis's $90 million Swiss factory to help solve cell therapy bottleneck
Swiss drugmaker Novartis's new $90 million cell and gene therapy factory in northern Switzerland is on track to begin commercial production of treatments, including Kymriah for cancer and Zolgensma for spinal muscular atrophy, in 2020.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
More News: Cancer | Cancer & Oncology | Gene Therapy | Genetics | Health | Spinal Muscular Atrophy | Switzerland Health